小柯机器人

SARS单克隆抗体可用于中和新冠病毒
2020-05-20 20:43

瑞士Vir Biotechnology公司Davide Corti、美国华盛顿大学David Veesler等研究人员合作发现,SARS单克隆抗体可用于中和新冠病毒。相关论文于2020年5月18日在线发表在《自然》杂志上。

研究人员报道了多种针对SARS-CoV-2突刺(S)糖蛋白的单克隆抗体,这些抗体是从2003年感染SARS-CoV个体的记忆B细胞中鉴定出来的。一种名为S309的抗体可以有效地中和SARS-CoV-2和SARS-CoV假病毒,并通过结合S受体结合结构域来中和真正的SARS-CoV-2。
 
使用冷冻电镜和结合测定法,研究人员表明S309可以识别sarbecovirus亚属内保守的聚糖表位,而不会与受体竞争。包含S309的抗体混合物以及鉴定到的其他抗体进一步增强了SARS-CoV-2中和作用,并可能限制中和逃逸突变体的出现。这些结果为使用含S309和S309的抗体混合物预防高暴露风险个体或作为限制或治疗严重疾病的疗法铺平了道路。
 
SARS-CoV-2是一种新出现的冠状病毒,与目前的COVID-19大流行有关,研发疫苗和治疗方案对于遏制这种人畜共患病毒的大流行至关重要。SARS-CoV-2突刺(S)糖蛋白促进进入宿主细胞,是中和抗体的主要靶标。
 
附:英文原文

Title: Cross-neutralization of SARS-CoV-2 by a human monoclonal SARS-CoV antibody

Author: Dora Pinto, Young-Jun Park, Martina Beltramello, Alexandra C. Walls, M. Alejandra Tortorici, Siro Bianchi, Stefano Jaconi, Katja Culap, Fabrizia Zatta, Anna De Marco, Alessia Peter, Barbara Guarino, Roberto Spreafico, Elisabetta Cameroni, James Brett Case, Rita E. Chen, Colin Havenar-Daughton, Gyorgy Snell, Amalio Telenti, Herbert W. Virgin, Antonio Lanzavecchia, Michael S. Diamond, Katja Fink, David Veesler, Davide Corti

Issue&Volume: 2020-05-18

Abstract: SARS-CoV-2 is a newly emerged coronavirus responsible for the current COVID-19 pandemic that has resulted in more than 3.7 million infections and 260,000 deaths as of 6 May 20201,2. Vaccine and therapeutic discovery efforts are paramount to curb the pandemic spread of this zoonotic virus. The SARS-CoV-2 spike (S) glycoprotein promotes entry into host cells and is the main target of neutralizing antibodies. Here we describe multiple monoclonal antibodies targeting SARS-CoV-2 S identified from memory B cells of an individual who was infected with SARS-CoV in 2003. One antibody, named S309, potently neutralizes SARS-CoV-2 and SARS-CoV pseudoviruses as well as authentic SARS-CoV-2 by engaging the S receptor-binding domain. Using cryo-electron microscopy and binding assays, we show that S309 recognizes a glycan-containing epitope that is conserved within the sarbecovirus subgenus, without competing with receptor attachment. Antibody cocktails including S309 along with other antibodies identified here further enhanced SARS-CoV-2 neutralization and may limit the emergence of neutralization-escape mutants. These results pave the way for using S309- and S309-containing antibody cocktails for prophylaxis in individuals at high risk of exposure or as a post-exposure therapy to limit or treat severe disease.

DOI: 10.1038/s41586-020-2349-y

Source: https://www.nature.com/articles/s41586-020-2349-y

Nature:《自然》,创刊于1869年。隶属于施普林格·自然出版集团,最新IF:43.07
官方网址:http://www.nature.com/
投稿链接:http://www.nature.com/authors/submit_manuscript.html


本期文章:《自然》:Online/在线发表

分享到:

0